Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Sanofi’s Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Patients

Posted by GlobeNewswire on June 19, 2026

-------- Original Version -----------

Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

-------- English Version ------------

Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

-------- Link if available ----------

No Link available